Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription Articles published in Oncol Rep Retrieve available abstracts of 67 articles: HTML format

Single Articles

May 2023
1. XIAO Z, Li M, Zhang X, Rong X, et al
   TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
   Oncol Rep. 2023;49:84.
   PubMed     Abstract available
   
   
   April 2023
2. ZHANG Y, Liu S, Zhao T, Dang C, et al
   [Corrigendum] METTL3‑mediated m6A modification of Bcl‑2 mRNA promotes non‑small cell lung cancer progression.
   Oncol Rep. 2023;49:65.
   PubMed     Abstract available
   
   
   
3. YANG ES, Do Y, Cheon SY, Kim B, et al
   Andrographolide suppresses aerobic glycolysis and induces apoptotic cell death by inhibiting pyruvate dehydrogenase kinase 1 expression.
   Oncol Rep. 2023;49:72.
   PubMed     Abstract available
   
   
   February 2023
4. ZHAO B, Zhang Y, Lu S, Li M, et al
   Macrophage renewal modes affect acquired resistance to gefitinib in EGFR‑mutant lung cancer PC‑9 cells.
   Oncol Rep. 2023;49:30.
   PubMed     Abstract available
   
   
   January 2023
5. LIANG X, Wu Q, Wang Y, Li S, et al
   MicroRNAs as early diagnostic biomarkers for nonsmall cell lung cancer (Review).
   Oncol Rep. 2023;49.
   PubMed     Abstract available
   
   
   
6. HAN P, Zhou J, Xiang J, Liu Q, et al
   Research progress on the therapeutic effect and mechanism of metformin for lung cancer (Review).
   Oncol Rep. 2023;49.
   PubMed     Abstract available
   
   
   December 2022
7. WANG M, Chen X, Fu G, Ge M, et al
   Glutathione peroxidase 2 overexpression promotes malignant progression and cisplatin resistance of KRASmutated lung cancer cells.
   Oncol Rep. 2022;48.
   PubMed     Abstract available
   
   
   
8. WANG Y, Li S, Weng L, Du H, et al
   LASS2 overexpression enhances early apoptosis of lung cancer cells through the caspasedependent pathway.
   Oncol Rep. 2022;48.
   PubMed     Abstract available
   
   
   
9. KAIRA K, Imai H, Kawasaki T, Hashimoto K, et al
   Potential of VEGFR2 expression as a predictive marker of PD1 blockade in patients with advanced NSCLC.
   Oncol Rep. 2022;48.
   PubMed     Abstract available
   
   
   
10. MIAO H, Hui H, Li H, Lin Y, et al
    PEDF inhibits nonsmall cell lung cancer proliferation by suppressing autophagy through downregulation of AMPKULK1 signaling.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    November 2022
11. SUMITOMO R, Huang CL, Ando H, Ishida T, et al
    Wnt2b and Wnt5a expression is highly associated with M2 TAMs in nonsmall cell lung cancer.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    October 2022
12. TAMARI S, Menju T, Toyazaki T, Miyamoto H, et al
    Nrf2/pFyn/ABCB1 axis accompanied by pFyn nuclear accumulation plays pivotal roles in vinorelbine resistance in nonsmall cell lung cancer.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    
13. HUANG Y, Wang X, Hu R, Pan G, et al
    SOX2 regulates paclitaxel resistance of A549 nonsmall cell lung cancer cells via promoting transcription of ClC3.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    September 2022
14. ZHANG G, Zheng H, Wang L
    miR4913p functions as a tumor suppressor in nonsmall cell lung cancer by targeting fibroblast growth factor 5.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    
15. ZHU H, Xu X, Zheng E, Ni J, et al
    LncRNA RP11805J14.5 functions as a ceRNA to regulate CCND2 by sponging miR34b3p and miR1395p in lung adenocarcinoma.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    August 2022
16. AN W, Zhang Y, Lai H, Zhang Y, et al
    Alpinia katsumadai Hayata induces growth inhibition and autophagyrelated apoptosis by regulating the AMPK and Akt/mTOR/p70S6K signaling pathways in cancer cells.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    
17. ZHANG J, Wang J, Wu J, Huang J, et al
    UBE2T regulates FANCI monoubiquitination to promote NSCLC progression by activating EMT.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    July 2022
18. LI H, Zhong R, He C, Tang C, et al
    Colonystimulating factor CSF2 mediates the phenotypic plasticity of smallcell lung cancer by regulating the pSTAT3/MYC pathway.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    
19. ZHOU F, Nie L, Feng D, Guo S, et al
    [Retracted] MicroRNA379 acts as a tumor suppressor in nonsmall cell lung cancer by targeting the IGF1Rmediated AKT and ERK pathways.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    
20. HUANG X, Jiang L, Lu S, Yuan M, et al
    Overexpression of ERCC6L correlates with poor prognosis and confers malignant phenotypes of lung adenocarcinoma.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    June 2022
21. YAMAZAKI K, Hoshi M, Tezuka H, Morita N, et al
    Dallose enhances the efficacy of hydroxychloroquine against Lewis lung carcinoma cell growth by inducing autophagy.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
22. ZHU F, Ren Z
    Icariin inhibits the malignant progression of lung cancer by affecting the PI3K/Akt pathway through the miR2055p/PTEN axis.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    April 2022
23. SUZUKI T, Sirimangkalakitti N, Baba A, Toyoshima-Nagasaki R, et al
    Characterization of the nucleotide excision repair pathway and evaluation of compounds for overcoming the cisplatin resistance of nonsmall cell lung cancer cell lines.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
24. SUMITOMO R, Huang CL, Fujita M, Cho H, et al
    Differential expression of PDL1 and PDL2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in nonsmall cell lung cancer.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
25. CAO J, Yu U, Li L, Yuan X, et al
    circKL inhibits the growth and metastasis of kidney cancer by sponging miR1825p and upregulating FBXW7.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    March 2022
26. CHEN N, Zhou YS, Wang LC, Huang JB, et al
    Advances in metforminbased metabolic therapy for nonsmall cell lung cancer (Review).
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
27. SHI Q, Shi QN, Xu JW, Wang HY, et al
    rs9390123 and rs9399451 influence the DNA repair capacity of lung cancer by regulating PEX3 and PHACTR2AS1 expression instead of PHACTR2.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
28. WANG Y, Chen J, Huang Y, Yang S, et al
    Schisandrin B suppresses osteosarcoma lung metastasis in vivo by inhibiting the activation of the Wnt/betacatenin and PI3K/Akt signaling pathways.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    February 2022
29. LI Z, Li B, Niu L, Ge L, et al
    [Retracted] miR592 functions as a tumor suppressor in human nonsmall cell lung cancer by targeting SOX9.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
30. HORIBE S, Ishikawa K, Nakada K, Wake M, et al
    Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
31. FUJII Y, Amatya VJ, Kushitani K, Suzuki R, et al
    Downregulation of lncRNA PVT1 inhibits proliferation and migration of mesothelioma cells by targeting FOXM1.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    January 2022
32. KEERATICHAMROEN S, Lirdprapamongkol K, Thongnest S, Boonsombat J, et al
    JAK2/STAT3mediated dosedependent cytostatic and cytotoxic effects of sesquiterpene lactones from Gymnanthemum extensum on A549 human lung carcinoma cells.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
33. SONODA D, Kamizaki K, Matsuo Y, Aruga K, et al
    Characterization of morphological alterations in micropapillary adenocarcinoma of the lung using an established cell line.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
34. FAN M, Arai M, Tawada A, Chiba T, et al
    Contrasting functions of the epithelialstromal interaction 1 gene, in human oral and lung squamous cell cancers.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    November 2021
35. ZENG Y, Lv X, Du J
    Natural killer cellbased immunotherapy for lung cancer: Challenges and perspectives (Review).
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    October 2021
36. HUA X, Chu H, Wang C, Shi X, et al
    Targeting USP22 with miR305p to inhibit the hypoxiainduced expression of PDL1 in lung adenocarcinoma cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    September 2021
37. CHANG CY, Wu KL, Chang YY, Tsai PH, et al
    Amine oxidase, copper containing 3 exerts antimesenchymal transformation and enhances CD4(+) Tcell recruitment to prolong survival in lung cancer.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
38. ZHANG Y, Yao H, Li Y, Yang L, et al
    Circular RNA TADA2A promotes proliferation and migration via modulating of miR638/KIAA0101 signal in nonsmall cell lung cancer.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
39. JIN C, Shi L, Li K, Liu W, et al
    Mechanism of tumorderived extracellular vesicles in regulating renal cell carcinoma progression by the delivery of MALAT1.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
40. WANG WJ, Wang J, Ouyang C, Chen C, et al
    Overview of serpin B9 and its roles in cancer (Review).
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    August 2021
41. KIM MK, Choi MJ, Lee HM, Choi HS, et al
    Heterogeneous nuclear ribonucleoprotein A2/B1 regulates the ERK and p53/HDM2 signaling pathways to promote the survival, proliferation and migration of nonsmall cell lung cancer cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
42. LIN CC, Liao WT, Yang TY, Lu HJ, et al
    MicroRNA10b modulates cisplatin tolerance by targeting p53 directly in lung cancer cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
43. ZHANG X, He Y, Jiang Y, Bao Y, et al
    TMEM229A suppresses nonsmall cell lung cancer progression via inactivating the ERK pathway.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
44. LU R, Zhou Q, Ju L, Chen L, et al
    Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
45. MA J, Yan T, Bai Y, Ye M, et al
    TMEM100 negatively regulated by microRNA106b facilitates cellular apoptosis by suppressing survivin expression in NSCLC.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
46. YANG L, Li N, Wang M, Zhang YH, et al
    Tumorigenic effect of TERT and its potential therapeutic target in NSCLC (Review).
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
47. ZHANG Y, Liu S, Zhao T, Dang C, et al
    METTL3mediated m6A modification of Bcl2 mRNA promotes nonsmall cell lung cancer progression.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
48. ZHU Y, Chen QY, Jordan A, Sun H, et al
    RUNX2/miR31/SATB2 pathway in nickelinduced BEAS2B cell transformation.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    July 2021
49. ZINNAH KMA, Park SY
    Sensitizing TRAILresistant A549 lung cancer cells and enhancing TRAILinduced apoptosis with the antidepressant amitriptyline.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
50. ZENG T, Xu M, Zhang W, Gu X, et al
    Autophagy inhibition and microRNA199a5p upregulation in paclitaxelresistant A549/T lung cancer cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    June 2021
51. BUACHAN P, Namsa-Aid M, Sung HK, Peng C, et al
    Inhibitory effects of terrein on lung cancer cell metastasis and angiogenesis.
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    
52. GAO L, Yang T, Zhang S, Liang Y, et al
    EHF enhances malignancy by modulating AKT and MAPK/ERK signaling in nonsmall cell lung cancer cells.
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    
53. LI S, Wang H, Ma R, Wang L, et al
    Schisandrin B inhibits epithelialmesenchymal transition and stemness of largecell lung cancer cells and tumorigenesis in xenografts via inhibiting the NFkappaB and p38 MAPK signaling pathways.
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    
54. WANG Z, Zhang X, Tian X, Yang Y, et al
    CREB stimulates GPX4 transcription to inhibit ferroptosis in lung adenocarcinoma.
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    
55. GLATZEL-PLUCINSKA N, Piotrowska A, Rzechonek A, Podhorska-Okolow M, et al
    SATB1 protein is associated with the epithelialmesenchymal transition process in nonsmall cell lung cancers.
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    May 2021
56. HE Q, Dong Y, Zhu Y, Ding Z, et al
    TMEM100 induces cell death in nonsmall cell lung cancer via the activation of autophagy and apoptosis.
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    
57. WANG H, Zhang P
    lncRNACASC15 promotes osteosarcoma proliferation and metastasis by regulating epithelialmesenchymal transition via the Wnt/betacatenin signaling pathway.
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    
58. ZHOU X, Sun T, Meng Y, Luo J, et al
    BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells.
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    
59. ZHOU H, Geng F, Chen Y, Du J, et al
    The mineral dust-induced gene, mdig, regulates angiogenesis and lymphangiogenesis in lung adenocarcinoma by modulating the expression of VEGF-A/C/D via EGFR and HIF-1alpha signaling.
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    
60. LIN S, Tian C, Li J, Liu B, et al
    Differential MUC22 expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma.
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    April 2021
61. MURPHY A, Roy N, Sun H, Jin C, et al
    Induction of NUPR1 and AP1 contributes to the carcinogenic potential of nickel.
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    
62. HOSSIAN AKMN, Mackenzie GG, Mattheolabakis G
    Combination of miR143 and miR506 reduces lung and pancreatic cancer cell growth through the downregulation of cyclindependent kinases.
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    March 2021
63. YANG XG, Li YY, Zhao DX, Cui W, et al
    Repurposing of a monoamine oxidase A inhibitor‑heptamethine carbocyanine dye conjugate for paclitaxel‑resistant non‑small cell lung cancer.
    Oncol Rep. 2021;45:1306-1314.
    PubMed     Abstract available
    
    
    
64. LING B, Wei P, Xiao J, Cen B, et al
    Nucleolar and spindle‑associated protein 1 promotes non‑small cell lung cancer progression and serves as an effector of myocyte enhancer factor 2D.
    Oncol Rep. 2021;45:1044-1058.
    PubMed     Abstract available
    
    
    
65. GU X, Zhang J, Shi Y, Shen H, et al
    ESM1/HIF‑1alpha pathway modulates chronic intermittent hypoxia‑induced non‑small‑cell lung cancer proliferation, stemness and epithelial‑mesenchymal transition.
    Oncol Rep. 2021;45:1226-1234.
    PubMed     Abstract available
    
    
    January 2021
66. ZHOU X, Liu B, Ning Q, Xia Z, et al
    Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFRmutated NSCLC cells in vitro and in vivo via STAT3/Bcl2 signaling.
    Oncol Rep. 2021;45:217-229.
    PubMed     Abstract available
    
    
    October 2020
67. XU L, Qu JL, Song N, Zhang LY, et al
    Biological and clinical significance of flap endonuclease1 in triplenegative breast cancer: Support of metastasis and a poor prognosis.
    Oncol Rep. 2020 Oct 16. doi: 10.3892/or.2020.7812.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: